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Abstract
Background: The epidemic rise of diabetes carries major negative public health and economic consequences
particularly for low and middle-income countries. The highest predicted percentage growth in diabetes is in the
sub-Saharan Africa (SSA) region where to date there has been no data on the incidence of diabetic retinopathy
from population-based cohort studies and minimal data on incident diabetes. The primary aims of this study were
to estimate the cumulative six-year incidence of Diabetes Mellitus (DM) and DR (Diabetic Retinopathy), respectively,
among people aged ≥50 years in Kenya.
Methods: Random cluster sampling with probability proportionate to size were used to select a representative
cross-sectional sample of adults aged ≥50 years in 2007-8 in Nakuru District, Kenya. A six-year follow-up was
undertaken in 2013–14. On both occasions a comprehensive ophthalmic examination was performed including
LogMAR visual acuity, digital retinal photography and independent grading of images. Data were collected on
general health and risk factors. The primary outcomes were the incidence of diabetes mellitus and the incidence of
diabetic retinopathy, which were calculated by dividing the number of events identified at 6-year follow-up by the
number of people at risk at the beginning of follow-up. Age-adjusted risk ratios of the outcomes (DM and DR
respectively) were estimated for each covariate using a Poisson regression model with robust error variance to
allow for the clustered design and including inverse-probability weighting.
Results: At baseline, 4414 participants aged ≥50 years underwent complete examination. Of the 4104 non-diabetic
participants, 2059 were followed-up at six-years (50 · 2%). The cumulative incidence of DM was estimated at 61 · 0
per 1000 (95% CI: 50 · 3–73 · 7) in people aged ≥50 years. The cumulative incidence of DR in the sample population
was estimated at 15 · 8 per 1000 (95% CI: 9 · 5–26 · 3) among those without DM at baseline, and 224 · 7 per 1000
(116.9–388.2) among participants with known DM at baseline. A multivariable risk factor analysis demonstrated
increasing age and higher body mass index to be associated with incident DM. DR incidence was strongly
associated with increasing age, and with higher BMI, urban dwelling and higher socioeconomic status.
Conclusions: Diabetes Mellitus is a growing public health concern with a major complication of diabetic
retinopathy. In a population of 1 · 6 million, of whom 150,000 are ≥50 years, we estimated that 1650 people aged
≥50 develop DM per year, and 450 develop DR. Strengthening of health systems is necessary to reduce incident
diabetes and its complications in this and similar settings.
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Background
The number of adults with Diabetes Mellitus (DM) in
Africa is predicted to double from 12 · 1 million in 2010
to 23 · 9 million in 2030 based on projections from
prevalence data [1]. The epidemic rise of DM carries
major public health and economic consequences for the
continent, particularly given it is home to some of the
fastest growing economies and most rapid transitions in
lifestyles conducive to DM ([http://unstats.un.org/unsd/
methods/m49/m49regin.htm - least]). Currently, there
are few incidence data from low and middle-income set-
tings, particularly sub-Saharan Africa (SSA), making it
difficult to plan screening and treatment services [2, 3].
DM causes visual impairment through cataract and
diabetic retinopathy (DR) [4], a progressive disease of
the retinal microvasculature. DR is not yet a leading
cause of blindness in sub-Saharan Africa, responsible for
just 2.8% of blindness [5]. However, it is likely to become
an increasingly important cause of blindness and visual
impairment, with the increasing prevalence of DM in
SSA, and improving control of other leading causes of
visual impairment such as cataract, uncorrected refract-
ive error and trachoma. Population-based incidence data
for DR are lacking for SSA, although some clinical
follow-up data are available [6].
Current strategies to control DM in SSA focus on health
system strengthening to enable a public health approach
to both prevent the onset of DM and create awareness of
the consequences of DM, including sight loss [7]. In
addition, efforts are also being scaled-up for the identifica-
tion of people with DM , and their enrolment in treatment
programmes [8]. Systematic DR screening in SSA is cur-
rently very limited, with only a small number of locations
having an active programme [9].
Data on the incidence and progression of DM and
DR are needed to estimate the current and future
burden of these conditions in order to inform service
development, and future research. The primary aims
of this study were to estimate the cumulative six-year
incidence of DM and DR in people aged ≥50 years in
Kenya. A secondary aim was to identify risk factors
for each of these outcomes.
Methods
The fieldwork was carried out in Nakuru district, Kenya,
which has a population of 1.6 million [accurate as of
2009], one third of which is urban. Nakuru is broadly
representative of Kenya in terms of ethnic diversity and
economic activities. The baseline survey took place from
January 2007 to November 2008, and the follow-up
survey from November 2012 to March 2014. Full details
of the methods at baseline and follow-up are presented
elsewhere [10–12].
Sampling strategy and recruitment at baseline
We selected 100 clusters of 50 people aged ≥50 years
through probability proportionate to size sampling,
using the electoral roll as the sampling frame. House-
holds were selected within clusters using a modified
compact segment sampling method [13]. The village
leaders produced a sketch map of the polling area. The
polling area was divided into segments each including
approximately 50 people aged ≥50 years. One segment
was chosen at random by drawing lots and all house-
holds in the segment were included in the sample
sequentially, until 50 people aged ≥50 years were identi-
fied. If the segment did not include 50 people aged
≥50 years then an additional segment was chosen at
random and sampling continued.
The enumeration team visited households, assisted by
a village guide, and invited all eligible participants aged
≥50 years to the examination clinic, held at a convenient
place in the cluster over the subsequent two days.
Eligible participants were defined as those aged ≥50 years
resident in the cluster (i.e. living there at least 6 months
per year) who had slept in the house either the night
before or were planning on sleeping in the house that
night. If an eligible person was absent then the survey
team revisited the household at least twice.
The six-year follow-up assessment was initiated by an
Advance Team who visited homes of baseline partici-
pants and confirmed their identity using National
Identity cards. The two advance teams comprised of one
nurse, one field officer and a driver or public transport.
During this visit they located individuals with assistance
from the guide, phone numbers when available and pre-
viously recorded GPS locations using a Garmin Oregon
450 Satellite Navigation device. In addition, the team ex-
plained details of the examination and obtained written/
thumb print informed consent as well as informing par-
ticipants about location and time of examination [11].
Data collection
Comprehensive data were collected at baseline and
follow-up, using comparable methods, including slit
lamp examination by an ophthalmologist at both time
points. Details of data collection are available elsewhere
[11, 14] with specific details provided here for the
current analyses.
Diabetes mellitus
A single random finger-prick blood sample was taken to
measure glucose (Accutrend GC system) at baseline and
at follow-up. At follow-up, in addition, subjects with a
random blood sugar greater than 11.1 mmol/L (Inter-
national Diabetes Federation (IDF) guidance at time of
baseline study), those with known DM (regardless of
random measure), evidence of DR on retinal imaging
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and a subset (chosen randomly within each cluster) with
random glucose between 7 and 11 mmol/L had an add-
itional capillary blood HbA1C (A1C Now+, Bayer).
Visual acuity (VA)
Two ophthalmic nurses measured presenting VA, which
was defined as the number of letters read correctly with-
out glasses if the participant did not have glasses or with
distance glasses if they had them. Each eye was tested
separately at 4 m using a reduced Logarithm of the Min-
imal Angle of Resolution (LogMAR) tumbling ‘E’ chart
[15] in a well illuminated area. If the subject’s vision was
too poor to read any letters on the chart at four meters,
then the subject was tested at one meter, then counting
fingers, hand movements, light perception or no light
perception.
Fundus photography
Pupil dilation was performed using one drop of tropica-
mide 1% and one drop of phenylephrine 2.5%. The par-
ticipants had two non-stereoscopic digital 450 fundus
photographs taken per eye by an ophthalmic clinical of-
ficer using a TRC-NW6S Non-Mydriatic Retinal Camera
with 10 megapixel Nikon D80 (TopCon®) at baseline and
a Haag-Streit DRS CentreVue + at follow-up. One image
was centred on the optic disc while the other was
centred on the macula.
Anthropometric data collection
At baseline and follow-up, a nurse recorded the blood
pressure of participants three times on the right arm of
the participant, at least five minutes apart after an initial
period of five minutes of rest using the Omron digital
automatic monitor (model HEM907). Weight was mea-
sured to the nearest kilogram using standard scales (Seca
761 scales) after the participant had removed all heavy
clothing and shoes. Height was measured to the nearest
centimetre while the participant stood without shoes
using a standardized stadiometer (Leicester Height
Measure). For weight and height the average of two
readings was recorded. Waist and hip circumferences
were measured with a tape to the nearest centimetre.
Interviews
Participants were interviewed by trained nurses. Infor-
mation was collected on demographic data, education
and asset ownership. People were asked whether their
mother tongue was “Kikuyu”, “Kalenjin” (the two largest
ethnic group in Nakuru County) or “other” to assign
ethnicity. Information was also collected on health
behaviour (smoking, alcohol use) and health status
(diagnosis of diabetes or hypertension, family history
and their treatment).
Grading of retinal images
Retinal images were forwarded to the Retinal Grading
Centre at Moorfields Eye Hospital Reading Centre
(MEHRC) London for grading DR. All images supplied by
the Nakuru Eye Study Group, regardless of quality, were
sent for grading. No manipulation of the images was
allowed while grading, other than using grey-scale for
viewing the images. All images were first categorized for
quality as excellent, good, borderline and ungradeable.
Next, the photographs were graded for DR based on
the UK National Guidelines on Screening for Diabetic
Retinopathy [16]. Each eye was classified for all people
with diabetes as: no DR, mild NPDR, moderate NPDR,
severe NPDR or proliferative DR, based on the following
criteria:
 No DR - no changes characteristic of diabetic
retinopathy visible on the images.
 Mild non-proliferative DR (NPDR) - micro
aneurysms (MAs) and retinal haemorrhages only
were seen.
 Moderate NPDR - in addition to MAs multiple
deep, round or blot haemorrhages were noted.
 Severe NPDR - the presence of features of NPDR
plus cotton wool spots. In this scenario the grader
was asked to search for vascular features of DR,
such as venous loop, venous beading and
Intra-retinal micro-vascular abnormality (IRMA). If
these were found, severe NPDR was graded.
 Proliferative DR (PDR) – as above, with new vessels
on the disc (NVD) new vessels elsewhere (NVE),
pre-retinal or vitreous haemorrhage or pre-retinal
fibrosis ± tractional retinal detachment were seen.
All images were graded by the senior grader. In case of
difficulties, the adjudicator (TP) adjudicated the images.
The adjudicator also looked at a random selection of 5% of
images to ensure quality control. Data were entered onto
Excel and checked for consistency by a data monitor.
Grading methods were the same at baseline and follow-up.
Data analysis
Definitions and statistical analyses
DM was defined as per WHO standards for population-
based studies: reported current medication (tablets or
insulin) or; diet control for diabetes or; random blood
glucose level ≥11 · 1 mmol/L [17]. At follow up the def-
inition included HbA1C when a result was possible.
HbA1C of > =7 · 0 was taken as confirmation of DM and
if <7 · 0 DM was excluded. An HbA1C result superseded
other measures of DM apart from self-reported and on
medication, in which case an HbA1C of <7 · 0 was taken
as well controlled DM and HbA1C > =7 · 0 of poorly
controlled DM.
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A continuous socio-economic score (SES) was pro-
duced for each participant using principal component
analysis based on asset ownership, household type and
education [18]. The score was divided into quartiles to
categorize the study participants into four socioeco-
nomic groups with a higher score representing higher
SES. Body Mass Index (BMI) was calculated as height
(meters)/weight (kilograms)2. The clusters were defined
as rural or urban according to the classification used by
the District Health Statistics office [19].
All participants who had complete examinations at
baseline who did not have DM or did not have DR were
considered “at-risk” for incident DM or DR, respectively.
Follow-up status at 6 years was categorised as i) Found
and examined; ii) Found and not examined; iii)
Deceased; iv) Moved away; or v) Unknown.
Statistical analysis was performed using STATA v13
(Stata Corp). All analysis accounted for the cluster
survey design using Taylor linearized variance estimation
to calculate standard errors.
Pearson chi-squared tests, corrected for the survey-
design were used to calculate p-values in order to assess
differences between participants seen and those lost to
follow-up (LTFU), and between those known to have
died and with unknown outcome status. Those who
were deceased were then excluded. Those followed up
but without complete records for all covariates at base-
line were also excluded. An inverse probability-
weighting (IPW) model [20] was developed to allow
estimation of cumulative incidence while accounting for
those LTFU. Multivariable logistic regression was used
to identify independent baseline covariates associated
with LTFU. Covariates for which there was evidence of
univariable association with being LTFU (p < 0.1) were
kept in a multivariable model. From this final model, the
probability of being followed-up was estimated, based
on the presence or absence of each of these baseline co-
variates. The inverse of this probability formed the
weighting to be applied in order to account for those
LTFU. The final step was to remove those individuals
LTFU from the cohort, so that all subsequent analysis
would be performed on only those with complete out-
come records, with IPW applied to account for those
LTFU. A sensitivity analyses for this approach involved a
complete records analysis (i.e. only including those
people who had complete records for outcome and all
variables in the analysis).
The six-year cumulative incidence of each outcome
was calculated by dividing the number of events identi-
fied at 6-year follow-up by the number of people at risk
at the beginning of follow-up. 95% confidence intervals
were estimated assuming a Poisson distribution of
events. This analysis was done for the population overall,
and stratified by key covariates. Age-adjusted risk ratios
of the outcomes (DM and DR respectively) were estimated
for each covariate using a Poisson regression model with
robust error variance to allow for the clustered design and
including IPW. For multivariable analysis, an initial model
was fitted that included those variables associated with
outcome in age-adjusted analysis (Wald p-value <0.05). A
backward stepwise approach was applied to obtain a final
multivariable model, removing variables with p > 0.05. Es-
timates were weighted to allow for any bias due to loss to
follow up by weighting using inverse probability weights
as described above. The six-year cumulative incidence was
then used to estimate the expected number of new DR
cases per year by multiplying the six-year incidence by the
estimated Kenyan population and dividing by six, with the
assumption that cumulative incidence was constant over
time. Annual cumulative incidence was also estimated
separately for men and women and in ten-year age
categories (50–59, 60–69, 70–79 and 80 + .
Results
Diabetes mellitus
At baseline, 4414 participants aged ≥50 years underwent
complete examination (response rate of 88 · 1%) and 4388
(99 · 4%) had DM status data available, of whom 287 (6 ·
5%) were diagnosed with DM (Fig. 1). Of the 4,101who had
no DM at baseline, 2059 (50 · 2%) were followed-up at six-
years. Complete DM status data at follow-up were available
on 2056 (99 · 9%) participants, of whom 123 (6 · 0%) were
newly diagnosed with DM at six-year follow-up (Fig. 1).
Baseline characteristics of individuals with known
baseline DM status data who were re-examined at
follow-up (participants) and those who were LTFU are
shown in Table 1. There was strong evidence that those
who were LTFU were less likely to be Kikuyu or Kalenjin
speakers and more likely to be from urban areas (p <
0.001). The mean follow-up time of all participants was
5 · 6 (SD 0 · 6) years and the median was 5 · 5 (interquar-
tile range (IQR): 5 · 0–6 · 1) years (referred to as “six-year
cumulative incidence” from here on).
Of the 123 participants who developed incident DM
by six-years, 64 diagnoses were self-reported and 59
were based on blood sugar readings. Of the 64 self-
reported subjects with DM, 35 (54 · 7%) had random and
HbA1C readings within normal limits and were consid-
ered “controlled DM”, and the remaining 29 were
“uncontrolled DM” (10 had high HbA1C only, three had
elevated random glucose data only (no HbA1C data)
and 16 had both a high random glucose and HbA1C).
Consequently, the cumulative incidence of DM was esti-
mated at 61 · 0 per 1000 (95% CI: 50 · 3,73 · 7) in people
aged ≥50 years when corrected for loss to follow-up.
The incidence of DM decreased with age in both men
and women, and was similar across the sexes (Table 2).
Based on recent census data, the number of incident
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cases was estimated by extrapolating to the Kenyan
population aged ≥50 years (Table 3), assuming an equal
incidence per year over the study period. In the popula-
tion of 1 · 6 million people in Nakuru, Kenya, approxi-
mately 150,000 individuals are aged ≥50 years, and of
these approximately 1650 will develop DM each.
Of the 287 participants with known DM from baseline,
54 (18.8%) were known to have died, 110 (38.3%) were
re-assessed and 123 (42.8%) were LTFU. All 110 people
with known DM at baseline were defined as having
known DM at follow-up regardless of self-report. Of
these, 70 (63 · 6%) self-reported as DM at follow-up, of
whom 20 (28 · 6%) were controlled. Of the 40 with
known DM at baseline who did not report as having
DM at follow-up, 32 (80 · 0%) were controlled. Of these,
25 had a normal random blood sugar at baseline but
self-reported as DM, four did not self-report but had a
high random blood sugar and three both self-reported
and had a high blood sugar.
Increased risk of incident DM was associated with the
following baseline variables: higher body mass index, urban
dwelling, higher socioeconomic status, hypertension, and
having no previous formal education (Table 4). A lower
incidence was found with increasing age, former alcohol
consumption and Kalenjin ethnicity. After adjustment for
confounding, increasing age and higher body mass index
remained associated with incident DM (Table 4).
Diabetic retinopathy
At baseline, 4414 participants aged ≥50 years underwent
complete examination (response rate of 88 · 1%) and
3281 (74 · 3%) had DR image data available, of whom
195 (5 · 9%) were diagnosed with DM at baseline (Fig. 2).
Of these 195 participants, 70 had DR at baseline. At
Fig. 1 Flowcharts of participant Diabetes Mellitus status in the Nakuru Eye Disease Cohort Study
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follow-up, 78 (40 · 0%) of the 195 participants with base-
line DM were seen, and 1562 (50 · 6%) of the 3086
participants without DM at baseline.
The baseline characteristics of those with complete
data for analysis (participants with a known DR status at
follow-up, based on retinal images), and those for whom
data was incomplete were similar. However a higher
proportion of those who had impaired vision at baseline
were not included in the DR incidence analysis, either
due to LTFU or ungradeable retinal images (Table 5).
Table 1 Baseline characteristics of all individuals with a known baseline DM status subdivided by their follow-up category
(participant, non-participant) at 6-year follow-up (N = 4388)
Participants Non-participants or not included in analysis
Baseline characteristics Missing values Followed-up
n = 2166 (49.4%)
Not followed-up Alive/Unknown/DM
status missing n = 1814 (41.3%)
p-value* Deceased
n = 408 (9.3%)
p-value**
Age in years, mean (SD) 0 62.7 (9.4) 62.6 (10.4) 0.84 71.6 (12.8) <0.001
Systolic BP in mmHg, mean (SD) 12 139.5 (23.5) 140.8 (24.8) 0.16 147.4 (30.3) <0.001
Diastolic BP in mmHg , mean (SD) 12 82.6 (13.0) 83.3 (13.6) 0.19 82.7 (16.5) 0.94
Random Blood Glucose, mean (SD) 92 5.1 (2.3) 5.3 (2.3) 0.12 5.7 (3.7) <0.001
Sex, % (n) Female 0 1025 (47.3%) 841 (46.4%) 0.59 236 (57.8%) <0.001
Male 1141 (52.7%) 973 (53.6%) 172 (42.2%)
BMI, % (n) Underweight
(<18.5 kg/m2)
42 267 (12.4%) 250 (14.0%) 0.52 99 (25.0%) <0.001
Normal
(18.5–24.99 kg/m2)
1091 (50.5%) 882 (49.2%) 199 (50.3%)
Overweight
(25–29.99 kg/m2)
506 (23.4%) 419 (23.4%) 66 (16.7%)
Obese
(30 + kg/m2)
295 (13.7%) 240 (13.4%) 32 (8.1%)
Vision status
impaired
(<6/12 better eye),
% (n)
Normal 17 1985 (91.7%) 1635 (90.8%) 0.36 306 (75.4%) <0.001
Impaired 180 (8.3%) 165 (9.2%) 100 (24.6%)
Tribe, % (n) Kikuyu 0 1393 (64.3%) 1079 (59.5%) <0.001 283 (69.4%) 0.09
Kalenjin 540 (24.9%) 380 (20.9%) 92 (22.5%)
Other 233 (10.8%) 355 (19.6%) 33 (8.1%)
Education, % (n) None 1 193 (8.9%) 204 (11.3%) 0.03 26 (6.4%) <0.001
Primary 687 (31.7%) 588 (32.4%) 179 (43.9%)
Secondary 1069 (49.4%) 806 (44.5%) 174 (42.6%)
Higher 217 (10.0%) 215 (11.9%) 29 (7.1%)
Residence, % (n) Rural 0 1636 (75.5%) 1014 (55.9%) <0.001 302 (74.0%) 0.59
Urban 530 (24.5%) 800 (44.1%) 106 (26.0%)
SES Quartile, % (n) Lower 22 514 (23.8%) 442 (24.5%) 0.01 136 (33.3%) 0.003
Middle lower 591 (27.4%) 404 (22.4%) 96 (23.5%)
Middle upper 557 (25.8%) 438 (24.3%) 97 (23.8%)
Upper 495 (22.9%) 517 (28.7%) 79 (19.4%)
Smokers, % (n) Never 0 1503 (69.4%) 1322 (72.9%) 0.007 255 (62.5%) 0.02
Former 163 (7.5%) 145 (8.0%) 33 (8.1%)
Current 500 (23.1%) 347 (19.1%) 120 (29.4%)
Alcohol, % (n) Never 5 882 (40.8%) 704 (38.9%) 0.10 117 (28.7%) <0.001
Former 942 (43.6%) 772 (42.6%) 221 (54.2%)
Current 339 (15.7%) 336 (18.5%) 70 (17.2%)
*P-value for association between the baseline characteristic and the odds of having a known DM status observation at follow up, amongst all participants
identified as non-diabetic at baseline and not known to be deceased at follow up
**P-value for association between the baseline characteristic and the odds of dying during the follow up period, amongst all participants identified as
non-diabetic at baseline and either followed up or known to be deceased at follow up (i.e. excluding the group who were not followed up)
Bastawrous et al. BMC Endocrine Disorders  (2017) 17:19 Page 6 of 14
Of the 1562 people without either DM or DR at base-
line, 1377 (88 · 1%) had complete follow-up DR status
data. Of these, 89/1377 (6 · 5%) were newly diagnosed
with DM; and 9 (10 · 1%) had incident DR. A further 11
incident cases of DR were seen in the 44 participants
with DM but no DR at baseline (Fig. 2). Therefore, in
total, 20 participants developed DR during follow up,
giving a corrected cumulative incidence of 15 · 8 per
1000 (95% CI: 9 · 5–26 · 3), Table 2. This equates 15,800
cases in the population aged ≥50 years per year per
million. In the population of 1 · 6 million people in
Nakuru, Kenya, approximately 150,000 individuals are
aged ≥50 years, and of these approximately 1650 will de-
velop DM each year and 450 will develop DR each year.
Among subjects with known DM at baseline, the cor-
rected cumulative incidence of DR is 224 · 7 per 1000
(95% CI: 116 · 9–388 · 2) (Table 2). Similarly to DM, the
incidence of DR decreased with increasing age (Table 2).
Of the 20 incident cases of DR, seven had sight-
threatening DR (STDR) of whom two cases were prolif-
erative DR (five with severe retinopathy), four cases had
moderate DR and nine mild DR (Table 2).
In total 23 participants with known DR at baseline
were followed up and had a gradable retinal image. Of
these, 15 still had signs of DR, while eight no longer had
evidence of DR. Of nine with background DR at baseline,
one progressed to pre-proliferative DR and the remainder
either remained BDR (n = 2) or had no signs of DR at
follow-up (n = 6). Of seven participants with moderate
non-proliferative DR (NPDR) at baseline, three progressed
to proliferative DR (PDR). One participant with severe
NPDR at baseline developed PDR and one remained
Severe NPDR. Of five with PDR at baseline, one regressed
to Moderate NPDR (having undergone pan-retinal photo-
coagulation) and the other four remained PDR, of whom
two had evidence of laser treatment.
Multivariable analysis of incident DR (Table 6) was not
conducted due to the small number of participants in
the category (n = 20). However, the age-adjusted risk
ratio suggested a correlation between increasing inci-
dence of DR and higher BMI, urban dwelling and higher
socioeconomic status. No conclusions can be drawn
from this due to the wide 95% confidence intervals.
Discussion
This population-based cohort study of people aged 50+
in rural Kenya is the first, to our knowledge, to assess
the incidence of DM and DR in SSA. The six-year
Table 2 Age-gender–specific 6-year cumulative incidence of diabetes mellitus among the Nakuru eye disease cohort study
participants
Male Female Overall
Age group
(years)
N
(Cases / at risk)
Risk per 1000/6 years
(95% CI)a
N Risk per 1000/6 years
(95% CI)a
N Risk per 1000/6 years
(95% CI)a
Diabetes Mellitus (N = 2056)
50–59 24 / 393 63.7(43.0,93.3) 37 / 544 69.6(49.2,97.7) 61 / 937 67.1(52.2,85.8)
60–69 19 / 328 62.3(39.2,97.6) 22 / 326 67.0(42.6103.8) 41 / 654 64.7(46.3,89.5)
70–79 8 / 180 48.2(22.2101.5) 9 / 151 57.5(29.9107.8) 17 / 331 52.6(33.0,82.7)
80+ 3 / 66 40.3(12.3123.9) 1 / 68 11.9(1.6,84.9) 4 / 134 25.8(9.6,67.5)
All ages 54 / 967 58.6(44.7,76.4) 69 / 1089 63.0(48.8,81.1) 123 / 2056 61.0(50.3,73.7)
Diabetic Retinopathy – among those without DM and without DR at baseline (N = 1421)
50–59 5 / 297 24.6(8.5,68.9) 7 / 394 20.0(7.8,50.3) 12 / 691 22.0(11.0,43.4)
60–69 5 / 237 22.9(9.8,53.0) 1 / 229 3.9(0.5,28.5) 6 / 466 13.3(5.4,32.8)
70–79 2 / 123 15.2(3.6,61.4) 0 / 89 – 2 / 212 8.6(2.1,34.8)
80 + b 0 / 29 – 0 / 23 – 0 / 52 –
All ages 12 / 686 20.5(10.9,38.2) 8 / 735 11.5(4.8,27.1) 20 / 1421 15.8(9.5,26.2)
Diabetic Retinopathy – among those with DM at baseline, but without DR at baseline (N = 44)
50–59 3 / 8 400.4(83.3830.7) 3 / 14 198.9(46.8556.8) 6 / 22 278.3(111.7541.7)
60–69 4 / 10 409.8(130.2763.1) 0 / 4 – 4 / 14 268.8(78.8612.2)
70–79 1 / 4 175.5(2.7943.6) 0 / 2 – 1 / 6 126.8(6.3770.0)
80 + b 0 / 1 – 0 / 1 – 0 / 2 –
All ages 8 / 23 337.7(162.1573.3) 3 / 21 118.8(29.7372.5) 11 / 44 224.7(116.9388.2)
aEstimated using inverse probability weights to account for loss to follow up
bNo-one with DR at follow up among 80+ group
Risk of the outcome in the 6-year follow up, adjusted for loss to follow up using inverse probability weightings
Sample sizes are small for the DR analyses, so estimates have a wide confidence interval
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cumulative incidence of DM in this study was 61 cases
per 1000, equating to approximately 10 new cases per
1000 of population aged ≥50 per year. Longo-Mbenza et
al. investigated the incidence of type 2 DM in a pro-
spective cohort of 807 subjects of Central Africans aged
≥40 years over a four-year period, all of whom had no
DM at basline [2]. During the follow up, there were 93
incident DM cases (11 · 5%), corresponding to an inci-
dence of 29 (95% CI 15-43) per 1000 persons per year,
considerably higher than our estimated cumulative inci-
dence. Motola et al. investigated the incidence of DM in
a prospective cohort of 563 South African Indians with
no-DM aged 15 years or greater over a ten-year period.
During the follow up period there were 91 (16.2%) inci-
dent cases of DM, corresponding to an incidence (age
and sex-adjusted) cumulative incidence of 8.3 per 1000
persons per year [21]. This latter estimate was more in
line with ours, but included a much younger population.
The six-year cumulative incidence of DR among per-
sons, 50 years and over, with known DM was 225 cases
per 1000 (95%CI: 116 · 9388 · 2). There is minimal com-
parable data available for SSA. One systematic review of
62 studies that reported the prevalence or incidence of
DR in SSA [6] found few high-quality population-based
studies and the majority were hospital or clinic based
surveys. Two cohort studies of DR have been conducted
in SSA. Sixty-four patients with insulin-dependent (Type
1) DM (IDDM) in Soweto, South Africa were followed
over a 10-year period between 1982 and 1992. In those
subjects seen at 10 years, prevalence of DR had in-
creased from 6 to 52% and PDR from 0 to 3%, but no
incidence data was reported [22]. In a two-year pro-
spective cohort study of DR in Malawi, 357 subjects
were systematically sampled from two primary care dia-
betes clinics, and 295 participants were followed up. The
incidence of any DR over the follow-up period was 380
Table 3 Extrapolated number of new adults, per year, aged 50 years and over in Kenya with diabetes mellitus and diabetic
retinopathy based on incidence data (adjusted to take account of loss to follow up) and estimates of the population in Kenya by
age group in 2015
Male Female Overall
Age group
(years)
Extrapolated
number
Lower
(95% CI)
Upper
(95% CI)
Extrapolated
number
Lower
(95% CI)
Upper
(95% CI)
Extrapolated
number
Lower
(95% CI)
Upper
(95% CI)
Diabetes Mellitus
50–59 10,710 7230 15,690 12,760 9020 17,910 23,570 18,340 30,140
60–69 5350 3370 8390 7400 4700 11,460 12,690 9080 17,560
70–79 1950 900 4100 3010 1570 5650 4880 3060 7680
80+ 490 150 1500 200 30 1430 750 280 1950
All ages 17,910 13,660 23,350 22,860 17,710 29,390 40,780 33,630 49,270
Diabetic Retinopathy – among those without DM and those without DR
50–59 4230 1460 11,860 3850 1500 9690 8020 4020 15,840
60–69 2090 890 4820 450 60 3300 2760 1110 6770
70–79 640 150 2610 – – – 840 200 3410
80+ – – – – – – – – –
All ages 6520 3460 12,160 4390 1850 10,340 11,100 6670 18,370
Diabetic Retinopathy – among those without DR at baseline
50–59 1650 340 3430 1850 430 5170 3790 1520 7390
60–69 2090 660 3880 – – – 2840 830 6470
70–79 370 10 1980 – – – 620 30 3780
80+ – – – – – – – – –
All ages 4300 2070 7310 2260 570 7100 7080 3690 12,240
All are based on 2015 estimates of population
Diabetes Mellitus: Population at risk are all adults over 50 who do not have DM. To estimate the size of the population at risk the 2008 DM prevalence is used.
Expected number of new DM diagnoses in 50+ year old individuals per year is (population at risk x risk per 1000/6 years)/(6 × 1000)
Diabetic Retinopathy among those with no DM and without DR at baseline: Population at risk are all adults over 50 who do not have DR. To estimate the size of the
population at risk the 2008 DR prevalence is used. Expected number of new DR diagnoses in 50+ year old individuals per year is (population at risk x risk
per 1000/6 years)/(6 × 1000)
Diabetes Retinopathy among those with DM out without DR at baseline: Population at risk are all adults over 50 who have DM but do not have DR. To estimate the
size of the population at risk the 2008 DR prevalence is used. Expected number of new DR diagnoses in those 50+ year old with DM per year is (population at risk
x risk per 1000/6 years)/(6 × 1000)
Sample sizes are small for the DR analyses, so estimates have wide confidence intervals
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Table 4 Age-adjusted and multivariable analysis of a number of baseline co-variables and incident diabetes mellitus in the
Nakuru eye disease cohort study
Study sample, n = 2056
No at risk of diabetes
mellitus
Incident diabetes
mellitus
Risk per 1000/6 years
(95% CI)
Age adjusted risk ratio
(95% CI)
Multivariable adjusted risk ratio
(95% CI)a
Age
50–59 937 61 67.1 (52.2–85.8) Baseline Baseline
60–69 654 41 64.7 (46.3–89.5) 0.96 (0.64–1.45) 1.10 (0.74–1.63)
70–79 331 17 52.6 (33.0–82.7) 0.78 (0.47–1.30) 1.05 (0.64–1.72)
80+ 134 4 25.8 (9.6–67.5) 0.38 (0.14–1.05) 0.58 (0.21–1.59)
Gender
Male 967 54 58.6 (44.7–76.4) Baseline –
Female 1089 69 63.0 (48.8–81.0) 1.06 (0.74–1.51) –
BMI (5 missing values)
Underweight 260 5 17.5 (6.1–49.2) Baseline Baseline
Normal 1050 29 27.4 (18.5–40.4) 1.54 (0.50–4.79) 1.54 (0.50–4.79)
Overweight 465 54 120.4 (91.6–156.8) 6.69 (2.26–19.81) 6.69 (2.26–19.81)
Obese 276 34 123.3 (85.9–173.8) 6.83 (2.28–20.49) 6.83 (2.28–20.49)
Location
Rural 1571 79 48.6 (39.2–60.1) Baseline –
Urban 485 44 87.0 (63.5–118.2) 1.75 (1.20–2.56) –
SES Quartile (9 missing values)
Lower 504 15 28.9 (17.9–46.5) Baseline –
Lower middle 576 26 46.8 (31.4–69.3) 1.59 (0.87–2.89) –
Upper middle 520 40 75.4 (54.7–103.2) 2.54 (1.47–4.36) –
Upper 447 41 94.3 (71.7–123.1) 3.12 (1.80–5.40) –
Smoker
Never 1426 88 62.6 (49.9–78.2) Baseline –
Former 161 4 31.4 (9.4–100.2) 0.50 (0.15–1.63) –
Current 469 31 66.8 (47.8–92.7) 1.08 (0.73–1.62) –
Hypertension (7 missing values)
No 1084 44 43.3 (31.6–59.2) Baseline –
Yes 965 78 80.3 (64.1–100.3) 1.94 (1.33–2.82) –
Alcohol (3 missing values)
Never 835 60 73.0 (55.6–95.2) Baseline –
Former 891 42 47.5 (35.3–63.7) 0.68 (0.46–1.00) –
Current 327 20 66.7 (41.8–104.9) 0.94 (0.55–1.61) –
Ethnic group
Kikuyu 1308 86 68.2 (53.5–86.6) Baseline –
Kalenjin 530 23 42.6 (28.3–63.6) 0.62 (0.40–0.98) –
Other 218 14 60.5 (35.6–101.1) 0.84 (0.45–1.54) –
Education level
No education 173 14 88.9 (56.1–13.8) 1.77(1.01–3.12) –
Primary 665 32 45.7 (31.8–65.4) Baseline –
Secondary 1009 61 61.6 (46.9–80.5) 1.25 (0.80–1.95) –
College/Uni 209 16 80.0 (48.4–129.4) 1.58 (0.85–2.95) –
aFor multivariable analysis, an initial model was fitted that included those variables shown to be associated with outcome in age-adjusted analysis (using a Wald
test threshold p-value of <0.05 to indicate association). A backward stepwise approach was then applied in order to obtain a final
multivariable model, removing variables with p > 0.05 one-by-one
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Fig. 2 Flowcharts of participant Diabetic Retinopathy status in the Nakuru Eye Disease Cohort Study. DM: Diabetes Mellitus, DR: Diabetic Retinopathy
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per 1000 of population over two years [23]. Two of the
leading cohort studies of eye disease from high-income
settings, the Blue Mountains Study in Australia and The
Wisconsin Epidemiologic Study of Diabetic Retinopathy
(WESDR) in the United States in which comparable
methodology was used show estimates of incident DR
from Nakuru, Kenya are more than twice that of the
findings from Wisconsin and three times that of the
Blue Mountains Study. The Blue Mountains Study
reported 222 cases per 1000 over five years (44 per
Table 5 Baseline characteristics of all individuals with a known baseline DR status, subdivided by their follow-up category
(participant, non-participant) at 6-year follow-up (N = 3281)
Participants Non-participants or not included in analysis
Baseline characteristics Missing values Followed-up
n = 1444 (44.0%)
Not followed-up Alive/Unknown/DM
status missing n = 1555 (47.4%)
p-value* Deceased
n = 282 (8.6%)
p-value**
Age in years, mean (SD) 0 61.4 (8.6) 62.7 (10.2) 0.015 69.6 (11.8) <0.001
Systolic BP in mmHg, mean (SD) 8 138.6 (23.6) 140.4 (24.1) 0.084 145.2 (29.6) 0.001
Diastolic BP in mmHg , mean (SD) 8 82.9 (13.0) 82.9 (13.1) 0.865 82.6 (16.4) 0.72
Random Blood Glucose, mean (SD) 69 5.1 (2.3) 5.2 (2.3) 0.10 5.5 (3.0) 0.04
Sex, % (n) Female 0 701 (48.5%) 746 (48.0%) 0.78 172 (61.0%) <0.001
Male 743 (51.5%) 809 (52.0%) 110 (39.0%)
BMI, % (n) Underweight
(<18.5 kg/m2)
11 166 (11.5%) 220 (14.2%) 0.07 68 (24.2%) <0.001
Normal
(18.5-24.99 kg/m2)
738 (51.2%) 757 (48.9%) 138 (49.1%)
Overweight
(25-29.99 kg/m2)
343 (23.8%) 360 (23.3%) 51 (18.1%)
Obese
(30 + kg/m2)
194 (13.5%) 211 (13.6%) 24 (8.5%)
Vision status
impaired (<6/12
better eye), % (n)
Normal 4 1375 (95.3%) 1415 (91.1%) <0.001 233 (82.9%) <0.001
Impaired 68 (4.7%) 138 (8.9%) 48 (17.1%)
Tribe, % (n) Kikuyu 0 912 (63.2%) 891 (57.3%) 0.001 191 (67.7%) 0.28
Kalenjin 358 (24.8%) 354 (22.8%) 63 (22.3%)
Other 174 (12.0%) 310 (19.9%) 28 (9.9%)
Education, % (n) None 1 129 (8.9%) 168 (10.8%) 0.004 20 (7.1%) 0.001
Primary 425 (29.4%) 518 (33.3%) 116 (41.1%)
Secondary 739 (51.2%) 685 (44.1%) 121 (42.9%)
Higher 151 (10.5%) 183 (11.8%) 25 (8.9%)
Residence, % (n) Rural 0 1062 (73.5%) 863 (55.5%) <0.001 199 (70.6%) 0.43
Urban 382 (26.5%) 692 (44.5%) 83 (29.4%)
SES Quartile, % (n) Lower 16 310 (21.6%) 385 (24.9%) 0.003 87 (30.9%) 0.03
Middle lower 399 (27.7%) 354 (22.9%) 63 (22.3%)
Middle upper 386 (26.8%) 380 (24.6%) 72 (25.5%)
Upper 343 (23.9%) 426 (27.6%) 60 (21.3%)
Smokers, % (n) Never 0 981 (67.9%) 1115 (71.7%) 0.02 167 (59.2%) 0.02
Former 113 (7.8%) 139 (8.9%) 23 (8.2%)
Current 350 (24.2%) 301 (19.4%) 92 (32.6%)
Alcohol, % (n) Never 3 586 (40.6%) 584 (37.6%) 0.06 82 (29.1%) 0.001
Former 624 (43.2%) 664 (42.8%) 147 (52.1%)
Current 233 (16.1%) 305 (19.6%) 53 (18.8%)
*P-value for association between the baseline characteristic and the odds of having a valid DM observation at follow up, amongst all participants identified as
having no diabetes at baseline and not known to be deceased at follow up
**P-value for association between the baseline characteristic and the odds of dying during the follow up period, amongst all participants identified as no-DM at
baseline and either followed up or known to be deceased at follow up (i.e. excluding the group who were not followed up)
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1000/year) and the WESDR study reported 327 cases
per 1000 over a four-year period (82 per 1000/year).
In a prospective cohort in southern Malawi, sampled
from two primary care diabetes clinics, the 2-year inci-
dence of sight-threatening DR (STDR) amongst 357 sub-
jects for subjects with no DR, BDR, and PDR at baseline
was 2 · 7% (95% confidence interval [CI], 0 · 1–5 · 3), 27 ·
3% (95% CI, 16 · 4–38 · 2), and 25 · 0% (95% CI, 0–67 · 4),
respectively [23].
The sample of participants with DR at both study time
points in the Nakuru cohort was too small to draw con-
clusions on the progression of DR. However, 23 partici-
pants over the six year follow up period had a DR
assessment at baseline and follow-up, of whom four pro-
gressed from non-STDR to STDR and of five with STDR
at baseline, one recovered to non-STDR and the other
four remained with STDR [23].
Strengths
This study is one of the first reports of DM and DR from
a population-based sample in SSA. The sampling meth-
odology ensures that the data is representative for the
population over 50 and minimised bias by sampling
from the community rather than from hospitals or
clinics. Retinal image data were collected for DR analysis
and images were independently graded at Moorfields
Eye Hospital Reading Centre.
Limitations
The definition of DM used in this study was based on a
single, non-fasting, capillary blood sample and did not
include fasting blood glucose samples and HbA1C mea-
sures were only available at follow-up. There was a high
loss to follow-up which creates potential for selection
bias however statistical methods were used to adjust for
this. This high LTFU was largely due to post-election
violence in the region between the two study time points
which led to mass displacement. The population under
Table 6 Age-adjusted analysis the association between a
number of baseline co-variables and incident DR amongst those
DR free at baseline in the Nakuru eye disease cohort study
Study sample, n = 1421
No at risk of
diabetic
retinopathy
Incident
diabetic
retinopathy
Risk per
1000/6 years
(95% CI)
Age adjusted
risk ratio
(95% CI)
Age
50–59 691 12 22.0 (11.0–43.4) Baseline
60–69 466 6 13.3 (5.4–32.8) 0.6 (0.2–2.0)
70–79 212 2 8.6 (2.1–34.8) 0.4 (0.1–1.9)
80+ 52 0 – –
Gender
Male 686 12 20.5 (10.9–38.2) Baseline
Female 735 8 11.5 (4.8–27.1) 0.5 (0.2–1.5)
BMI (2 missing values)
Underweight
166 1 5.3 (0.7–36.6) Baseline
Normal 727 5 8.1 (3.3–19.5) 1.5 (0.2–13.0)
Overweight 336 11 39.6 (20.3–75.9) 6.4 (0.8–53.6)
Obese 190 3 12.9 (4.1–40.2) 2.0(0.2–21.9)
Location
Rural 1053 12 11.6 (6.6–20.4) Baseline
Urban 368 8 23.5 (10.3–52.7) 1.8 (0.7–4.4)
SES Quartile (6 missing values)
Lower 309 1 3.0 (0.4–21.8) Baseline
Lower
middle
394 2 4.9 (1.2–19.4) 1.6 (0.4–6.9)
Upper
middle
380 9 25.1(13.1–47.5) 7.5 (1.0–58.1)
Upper 332 8 29.3 (13.3–63.3) 8.3 (1.0–66.9)
Smoker
Never 964 16 18.3 (10.0–33.1) Baseline
Former 113 0 – –
Current 344 4 14.3 (5.4–37.5) 0.8 (0.3–2.6)
Hypertension (2 missing values)
No 764 8 15.0 (6.0–36.7) Baseline
Yes 655 12 16.9 (9.3–30.3) 1.2 (0.4–3.6)
Alcohol (1 missing value)
Never 580 8 15.3 (6.5–35.6) Baseline
Former 611 9 15.0 (7.4–30.1) 1.1 (0.4–3.3)
Current 229 3 19.0 (4.1–83.5) 1.3 (0.2–7.9)
Ethnic group
Kikuyu 895 14 16.9 (10.3–27.8) Baseline
Kalenjin 357 3 8.5 (1.9–36.9) 0.5 (0.1–2.3)
Other 169 3 22.6 (7.2–69.1) 1.1 (0.4–3.0)
Table 6 Age-adjusted analysis the association between a
number of baseline co-variables and incident DR amongst those
DR free at baseline in the Nakuru eye disease cohort study
(Continued)
Education level
No
education
123 4 42.8 (15.3–114.2) Baseline
Primary 422 0 – –
Secondary 726 14 21.7(11.9–39.0) 0.6(0.2–1.9)
College/
Uni
150 2 12.6(3.0–51.6) 0.3(0.0–1.8)
For multivariable analysis, an initial model was fitted that included those
variables shown to be associated with outcome in age-adjusted analysis (using
a Wald test threshold p-value of <0.05 to indicate association). A backward
stepwise approach was then applied in order to obtain a final multivariable
model, removing variables with p > 0.05 one-by-one
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observation were ≥50 years and therefore the study does
not estimate the incidence of DM or DR in the popula-
tion under age 50 years.
Implications
As the diabetes epidemic continues, a greater under-
standing is required of the resources needed and level of
deployment of those resources within the health system
to respond appropriately. This includes primary
prevention of DM in the community, high treatment
coverage of persons with DM in primary care, and inclu-
sion of eye screening for people with DM as standard
practice. With good prevalence data on DM available in
many countries and regions in SSA and a growing
understanding of the natural history of the diseases in
different populations it should now be possible (within a
wide range of confidence and based on several assump-
tions) to estimate the conversion in the over 50s of those
without DM developing DM and DR.
Overall, DM is increasing in Africa probably related to
environmental factors such as increased access to proc-
essed foods and more sedentary lifestyles; this is likely to
increase in the next decade. The awareness of DM in the
community is still low [3] and public campaigns to raise
awareness as well as provide locally available DM
screening and counselling facilities is needed. It is also
important to consider detection of VTDR in the com-
munity and resourcing eye care providers with the
knowledge and tools to manage patients with STDR is
essential to ensure a high quality service and avoid sight
loss from DM. Specific planning data for the region
under investigation is provided in Table 7.
Conclusions
In a population of 1 · 6 Million in Nakuru County, Kenya:
150,000 are 50 years and over, we estimated that 1650
people over the age of 50 develop DM per year, and 450
develop DR. The management of DM and DR is complex
and requires different approaches at different levels of the
healthcare system with considerable variation depending
on location. For effective planning at any level, high qual-
ity information is required to effectively plan the services.
This cohort provides some data to support planning and
is indicative of areas that need further research.
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Population at risk
Place Nakuru
County
Kenya
(National)
Total Population 1.6 Million 46 Million
Population 50 years and over 0.15 Million 4.3 Million
Diabetes Mellitus (DM)
Prevalence (%) of DM 6.5
Number of people over 50 with
DM (needing examination of the
retina every 1–2 years)
26,100 279,500
Awareness of DM within the
population over 50 (%)
85
Number of people over 50 with
known DM
22,185 237,575
Number over 50 who develop new
DM per 1000 of population per year
11/1000
Number over 50 who develop new
DM per sample population per year
1650 47,300
Diabetic Retinopathy (DR)
Proportion (%) of people over 50
with DM who have DR
35.9
Number of people over 50 with DR 9400 100,340
Number over 50 who develop new
DR per 1000 of population per year
3/1000
Number over 50 who develop new
DR of the sample population per year
450 12,900
Vision Threatening Diabetic Retinopathy (VTDR)
Proportion of people over 50 with
DM who have VTDR
13.4
Number of people over 50 with VTDR
(needing treatment)
1260 13,450
Number over 50 who develop new
VTDR per 1000 of population per year
1.6/1000
Number over 50 who develop new
VTDR of the sample population per year
240 6880
Further research needs to be done to assess gaps in the patient care pathway
which include:
• awareness of DM in the population;
• access / availability to relevant diagnostic and treatment services ;
• quality of diagnostic and treatment services;
• availability of screening for DR within diabetes and eye care;
• protocols and referral thresholds for people with or without DR;
• barriers to receiving treatment for STDR in those with known STDR
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